Results From Head-To-Head Phase 3 SEAM-PsA Study Assessing ENBREL and Methotrexate Regimens in Patients With Psoriatic Arthritis Presented at 2018 ACR/ARHP Annual Meeting
Additional Phase 3b Results Show Modified ENBREL Formulation Associated With Significantly Lower Mean Injection Site Pain Versus Prior Formulation
Data Presentations Result of Continued Dedication to Evaluate Optimal Use of ENBREL
PR Newswire
THOUSAND OAKS, Calif., Oct. 24, 2018